Biopharma M&A activity stayed strong through July 2026, with total deal value for the first seven months reaching $186.69 billion—13% higher than the comparable period in 2025. The update highlights how acquisition pace and upfront values rose despite monthly fluctuations, with May and June showing especially large prints. The same dataset also frames the market’s risk preference: buyers are prioritizing clinically de-risked assets. Together with the IPO and funding pipeline signals in the broader report set, the message is that capital continues to flow, but it is increasingly selective about late-stage probability.